# NIH Reporter #3R34AI198088-01S1

Aggressive antipyretics for neuroprotection and mortality reduction in CNS malaria: A Randomized-Controlled Trial

**Recipient:** University of Rochester

**Award Amount:** $8,952.00
**Ceiling:** $8,952.00

**Awarded:** September 08, 2026

**Identifier:** 3R34AI198088-01S1

A NIH-funded phase III randomized controlled trial led by University of Rochester to assess aggressive antipyretic therapy for neuroprotection and mortality reduction in pediatric CNS malaria.

### Description

This project involves a phase III randomized controlled trial to evaluate the efficacy of adjunctive aggressive antipyretic therapy in pediatric CNS malaria. The project is funded by NIH and involves international collaboration in Malawi, Zambia, and DRC. The primary outcome measures include mortality, neurodisability, and epilepsy within 3 years post-infection.

[View original record](https://reporter.nih.gov/search/0C83gI3MXki4-tEhFD4UKQ/project-details/11604353)